Ignite Creation Date:
2024-05-05 @ 7:26 PM
Last Modification Date:
2024-10-26 @ 9:49 AM
Study NCT ID:
NCT00675194
Status:
COMPLETED
Last Update Posted:
2008-05-20
First Post:
2008-05-06
Brief Title:
Efficacy of Irinotecan and Capecitabine Versusvs Cisplatin and Capecitabine in Patients With Esophago-Gastric Cancer
Sponsor:
Johannes Gutenberg University Mainz
Organization:
Johannes Gutenberg University Mainz
Study Overview
Official Title:
A Prospective Open Comparative Multicentre Phase II Study for the Evaluation of Irinotecan and Capecitabine Versus Cisplatin and Capecitabine in Advanced Gastric Adenocarcinoma or Gastric-Oesophagal Junction
Status:
COMPLETED
Status Verified Date:
2008-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to determine which Arm capecitabine irinotecan versus capecitabine cisplatin shows higher response rates in the treatment of advanced gastric-oesophagal cancer
Furthermore comparison of progression-free survival 1-year survival Quality of Life and safety
Furthermore comparison of progression-free survival 1-year survival Quality of Life and safety
Detailed Description:
capecitabine irinotecan versus capecitabine cisplatin as published by Kang et al ASCO 2006
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None